Business Context and Reporting Period
This Form 8-K, dated July 20, 2017, reports the completion of Virtu Financial, Inc.'s acquisition of Virtu KCG Holdings LLC (formerly KCG Holdings, Inc.). The transaction closed on July 20, 2017, with KCG becoming a wholly-owned subsidiary of Virtu. The filing also details concurrent financing arrangements, equity issuances, and changes to the Board of Directors.
Key Financial Metrics and Transaction Terms
- Acquisition Consideration: KCG shareholders received $20.00 in cash per share of Class A common stock, without interest, less applicable withholding taxes.
- Debt Assumption and Guarantees:
- Virtu assumed obligations for $500.0 million aggregate principal amount of 6.750% Senior Secured Second Lien Notes due 2022.
- Virtu assumed obligations for a $1,150.0 million first lien senior secured term loan (Term Loan Facility).
- Both debt instruments are secured by second-priority and first-priority liens, respectively, on substantially all assets of the Issuers and guarantors.
- Equity Issuances (Private Placements):
- Temasek: Issued 6,346,155 shares for approximately $99.0 million. Remaining 1,666,666 shares (~$26.0 million) expected by October 6, 2017.
- North Island Holdings (NIH): Issued 39,725,979 shares for approximately $613.5 million. Remaining 338,124 shares (~$5.2 million) expected by October 6, 2017.
- Share Count: 88,452,589 shares of Class A Common Stock outstanding as of the filing date; expected to reach 90,457,379 upon completion of remaining issuances.
Material Changes Versus Prior Period
The primary material change is the consolidation of KCG into Virtu Financial, significantly altering the company's asset base, debt structure, and capitalization. The filing does not provide comparative revenue, profit, or cash flow metrics for the combined entity versus the prior period; however, it references unaudited pro forma financial information filed as Exhibit 99.4 which details the combined results for the three months ended March 31, 2017, and the year ended December 31, 2016.
Guidance, Outlook, and Corporate Governance
- Board Changes: Vincent J. Viola resigned as Executive Chairman and was appointed Chairman Emeritus. Robert Greifeld was appointed Chairman, and Glenn Hutchins was appointed to the Board of Directors. Both new directors will serve on the Strategy Committee.
- Outlook and Risks: The filing includes standard forward-looking statements regarding integration strategies. Key risks include the inability to successfully implement integration, realize anticipated synergies, or achieve expected cost reductions within the projected timeframe.
- Regulatory Conditions: The issuance of the remaining shares to Temasek and NIH is subject to regulatory conditions and the absence of legal injunctions.
Investor Verification Checklist
- Verify the final closing price and total consideration paid to KCG shareholders against the $20.00 per share rate.
- Review the unaudited Pro Forma Condensed Combined Consolidated Financial Statements (Exhibit 99.4) to assess the combined entity's leverage and liquidity post-merger.
- Confirm the timing and conditions for the issuance of the remaining shares to Temasek and North Island Holdings.
- Examine the specific terms of the $500 million Second Lien Notes and the $1.15 billion Term Loan Facility regarding covenants and interest rates.
- Monitor the integration progress and realization of synergies as disclosed in future quarterly reports.